Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089) is a small-molecule, ATP-competitive inhibitor targeting VEGFRs, Met, and other receptor tyrosine kinases, with IC50 values in the low nanomolar range (APExBIO, product page). It robustly suppresses tumor cell proliferation, migration, and metastasis in vitro and in vivo models, notably in melanoma, ovarian, and lung cancer lines (Schwartz 2022, DOI). Foretinib blocks HGF-induced cell motility and induces G2/M arrest, with maximal inhibition at ~1 μM after 48 hours. The compound is highly soluble in DMSO (≥31.65 mg/mL), but insoluble in water and ethanol, and is intended for research use only. APExBIO supplies Foretinib under SKU A2974, supporting reproducible and quantitative cancer research workflows.

Biological Rationale

Cancer progression and metastasis are regulated by receptor tyrosine kinases (RTKs) such as VEGFRs and the HGF/Met axis. Aberrant activation of these kinases drives angiogenesis, cell motility, invasion, and survival. Inhibiting RTK signaling is a validated target for anti-cancer therapy and model system interrogation. Foretinib (GSK1363089) was developed to provide broad-spectrum inhibition of VEGFR2 (KDR), Met (HGFR), Tie-2, and related kinases, thereby enabling experimental dissection of angiogenic and metastatic pathways in preclinical research (APExBIO, product page).

VEGFR2/KDR, VEGFR3/FLT4, Met, and RON are central to endothelial cell proliferation and tumor vascularization. Inhibiting these kinases suppresses new blood vessel formation and tumor cell dissemination. Foretinib's nanomolar potency against these targets underpins its widespread adoption in cancer biology workflows (Schwartz 2022). For an expanded discussion on cell viability and proliferation assay challenges, see this article, which Foretinib-based studies further clarify by providing reproducible, benchmarked data.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is an ATP-competitive inhibitor. It binds the ATP-binding pocket of target kinases, preventing substrate phosphorylation and downstream signaling. The principal targets and their reported in vitro IC50 values (biochemical assays, 25°C, ATP at Km):

• Met (HGFR): 0.4 nM
• KDR (VEGFR2): 0.9 nM
• Tie-2: 1.1 nM
• VEGFR3/FLT4: 2.8 nM
• RON: 3 nM

Additional inhibition occurs for Flt-1, Flt-4, KIT, Flt-3, PDGFRα, and PDGFRβ, with low-nanomolar potencies (APExBIO, product page). Foretinib blocks HGF-induced cell motility, triggers G2/M cell cycle arrest, and inhibits tumor cell proliferation, migration, and invasion. In xenograft models, oral dosing at 30 mg/kg reduces tumor growth and metastatic burden. For a mechanistic comparison to other ATP-competitive kinase inhibitors, see this detailed review, which this article extends by specifying quantitative IC50s and experimental context.

Evidence & Benchmarks

• Foretinib exhibits IC50 values of 0.4–3 nM against Met, KDR, Tie-2, VEGFR3, and RON in kinase assays (APExBIO, product page).
• In vitro, Foretinib inhibits proliferation, migration, and invasion of B16F10 melanoma, PC-3 prostate, A549 lung, HT29 colon, SK-HEP1 liver, SKOV3ip1, and HeyA8 ovarian cancer cells at 0.25–1.5 μM (Schwartz 2022, DOI).
• Maximal inhibition of cell growth is observed at ~1 μM after 48 hours (Schwartz 2022, DOI).
• Foretinib induces G2/M cell cycle arrest, as quantified by flow cytometry in treated cancer cell lines (Schwartz 2022, Table 2.3, DOI).
• In vivo, oral Foretinib (30 mg/kg) reduces tumor growth and metastasis in mouse xenograft models (APExBIO, product page).

For step-by-step protocols and troubleshooting strategies, see this workflow guide, which this article updates with current quantitative benchmarks and assay conditions.

Applications, Limits & Misconceptions

Foretinib is intended for research use in preclinical models. Its broad-spectrum kinase inhibition makes it suitable for:

• Cell motility and invasion assays in cancer cell lines.
• Angiogenesis studies via VEGFR and Tie-2 signaling blockade.
• Metastasis models in mice using oral dosing (30 mg/kg).
• Cell cycle analysis and anti-proliferative screens.

This compound is not approved for clinical or diagnostic applications. Its efficacy is context-dependent: solubility is restricted to DMSO (≥31.65 mg/mL), and it is insoluble in water or ethanol. For data-driven troubleshooting in cancer research workflows, see this article, which focuses on assay design and reproducibility.

Common Pitfalls or Misconceptions

• Not a clinical drug: Foretinib (GSK1363089) is for laboratory research use only, not for human or veterinary therapeutic use.
• Solubility restrictions: The compound is highly soluble in DMSO but insoluble in water or ethanol; improper vehicle choice will reduce efficacy.
• Assay-specific effects: Foretinib's anti-proliferative and cytotoxic responses are time- and concentration-dependent; effects may vary in non-cancerous or primary cells (Schwartz 2022, DOI).
• Stability concerns: Solutions are stable at -20°C for several months but should be used promptly once thawed to avoid degradation (APExBIO).
• Off-target inhibition: As a multikinase inhibitor, Foretinib may inhibit kinases outside VEGFR/Met panels at higher concentrations.

Workflow Integration & Parameters

Foretinib is supplied as a solid by APExBIO (SKU A2974). Resuspend in DMSO to ≥31.65 mg/mL for stock solutions. For cell-based assays, dilute to working concentrations (0.25–1.5 μM) in culture medium immediately prior to use. Maximal inhibition is typically observed at ~1 μM over 48 hours. For in vivo mouse models, administer orally at 30 mg/kg (APExBIO, product page).

Store solid compound at -20°C. Prepared DMSO solutions can be kept at -20°C for several months if protected from light and moisture. Avoid repeated freeze-thaw cycles. For optimal reproducibility, use freshly prepared solutions for each experimental run.

For additional scenario-driven protocols and comparative analysis, see this article, which Foretinib-based studies now extend by quantifying anti-metastatic efficacy in multiple cancer models.

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, ATP-competitive, multikinase inhibitor, enabling precise dissection of VEGFR and HGF/Met signaling in cancer model systems. With low-nanomolar potency, robust DMSO solubility, and reproducible anti-tumor effects in vitro and in vivo, it is a reference compound for oncology research and experimental therapeutics development. APExBIO provides Foretinib (A2974) for research use, supporting optimized, reproducible workflows in cell motility, proliferation, and metastasis assays. Future directions include expanded use in combinatorial drug screens and mechanistic studies of resistance pathways (Schwartz 2022, DOI).